Not Medical Advice: This article is an educational review of scientific literature and does not account for individual health conditions. Always consult with healthcare professionals before making any health-related decisions.

The supplement aisle's favorite fertility promise

I actually saw a TODAY.com headline recently that said CoQ10 was "the No. 1 supplement an infertility doctor actually recommends." But walk into any supplement store looking for it, and you'll immediately see two options on the shelf: ubiquinone and ubiquinol. That ubiquinol bottle usually costs more, and the label will definitely tell you it's the "active" form with "superior absorption." Sounds like an easy choice.

But here's what's kind of weird. When you go looking for the fertility studies that made CoQ10 famous in the first place, you mostly find plain old CoQ10, not ubiquinol, powering the results.

The numbers that got everyone excited

So, a 2023 systematic review and meta-analysis actually pulled together nine randomized trials, covering 781 men dealing with idiopathic male infertility ^[1]. CoQ10 supplementation improved sperm concentration by a mean difference of 10.22 million per milliliter and total motility by about 5 percentage points ^[1]. Those are meaningful improvements for men starting from a deficit, though they wouldn't turn severely impaired semen parameters into textbook-normal.

Now, the pregnancy number is the one that really gets shared on social media. Clinical pregnancy odds were 6.02 times higher in the CoQ10 group compared to controls ^[1]. That odds ratio looks dramatic, but it came from a subset of the pooled data, and odds ratios in small fertility trials can swing wide. Still, a six-fold increase in odds gets attention for good reason.

One detail that often gets lost: that subgroup analysis actually showed sperm morphology (the shape of sperm, which matters for fertilization) only improved significantly when treatment lasted longer than three months ^[1]. According to research, shorter durations, such as a one-month trial period, may not be sufficient to fully realize the potential benefits of CoQ10.

The evidence from studies points to CoQ10 having a largely well-established safety profile. Three of the included studies reported no adverse effects, and one noted mild, transient side effects ^[1].

If it works for sperm, what about eggs?

A 2023 randomized controlled trial specifically enrolled 100 women who were classified as poor ovarian responders according to the Bologna criteria ^[2]. Half received CoQ10 plus folic acid for one month before and during their ICSI cycle; the other half received folic acid alone ^[2].

Honestly, the intermediate markers looked pretty encouraging. The CoQ10 group had significantly improved oocyte counts, higher peak estradiol levels, more antral follicles at the start of induction, and greater endometrial thickness ^[2]. More embryos were transferred in the treatment group, and fewer women ended up with no embryos to transfer at all ^[2].

Then the punchline. Chemical and clinical pregnancy rates between the two groups were statistically equivalent ^[2]. CoQ10 helped produce more of the raw materials, but the final outcome that patients care about most didn't budge.

This is a pattern worth paying attention to: better biomarkers not translating into better pregnancies. It doesn't mean CoQ10 failed. It was a one-month pre-treatment window, and the study's conclusion explicitly called for further research ^[2]. But it does mean the leap from "improved ovarian markers" to "higher chance of a baby" is still unproven in this population.

So where does ubiquinol fit into all of this?

A 2023 review examined ubiquinol specifically as a conditionally essential nutrient for reproduction ^[3]. The paper describes how ubiquinol enhances mitochondrial energy production and antioxidant defense in gametes, which appears to support sperm function, oocyte quality, and early embryo development ^[3]. It also points out that internal ubiquinol production may not meet heightened demands during reproductive years, especially with advancing parental age ^[3].

That's a compelling biological argument. CoQ10 exists in two forms: ubiquinone (oxidized) and ubiquinol (reduced). Ubiquinone is understood to be converted to ubiquinol for antioxidant activity, and research suggests that ubiquinol supplements generally offer superior bioavailability, particularly in older adults or those with impaired conversion capacity. Standard crystalline ubiquinone has notoriously poor oral bioavailability due to its high molecular weight and lipid solubility.

So the logic seems airtight: ubiquinol is better absorbed, reproduction needs more of it with age, therefore ubiquinol should be the fertility supplement of choice. Except the review is synthesizing mechanistic and preclinical rationale, not reporting a head-to-head clinical trial ^[3]. The meta-analysis that produced the six-fold pregnancy odds increase used studies of CoQ10 broadly ^[1]. The randomized trial in women with poor ovarian response also used CoQ10, not specifically ubiquinol ^[2].

This is the gap hiding in plain sight. The form with the strongest marketing story doesn't yet have the clinical trial outcomes backing it for fertility. The clinical outcomes came from the "inferior" form. Maybe ubiquinol would perform even better. Maybe the conversion from ubiquinone to ubiquinol happens efficiently enough in the reproductive population that it doesn't matter. Nobody has published the trial that answers this question.

💊 Bottom Line

The fertility evidence for CoQ10 is real but incomplete. In men, pooled trial data shows genuine improvements in sperm quality and pregnancy odds, with the caveat that treatment needs to last beyond three months to see the full effect ^[1]. In women with poor ovarian response, CoQ10 improved the biological markers of ovarian function without yet clearing the bar on pregnancy rates ^[2]. And the ubiquinol-versus-ubiquinone question that every supplement shopper agonizes over? It remains essentially unanswered in fertility research. The review literature makes a strong case for why ubiquinol should matter ^[3], but "should" and "demonstrated in a controlled trial" are different currencies. For now, the form with the clinical pregnancy data is simply "CoQ10."

---

References

[1] Bakri S, Saleh R, Cayan S, et al. Efficacy and Safety of Coenzyme Q10 in Idiopathic Male Infertility: A Systematic Review and Meta-Analysis of Randomized Trials. The world journal of men's health. 2025. PMID: 40878114
https://pubmed.ncbi.nlm.nih.gov/40878114/

[2] Abdelrahman M, Gamal M, Salem S, et al. Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study. Drug design, development and therapy. 2026. PMID: 41800295
https://pubmed.ncbi.nlm.nih.gov/41800295/

[3] Derbyshire E, Ostojic S, Alahmar A. Ubiquinol in Fertility and Reproduction: A Conditionally Essential Nutrient for Critical Early-Life Stages. Nutrients. 2026. PMID: 41515272
https://pubmed.ncbi.nlm.nih.gov/41515272/